Last reviewed · How we verify

NCT05896501

Role of FFR in ACS Patients: Pressure ACS Registry

Active, enrolled Last updated 2 October 2024
What this trial tests

trial testing Fractional Flow Reserve in Acute Coronary Syndrome in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2020
Primary endpoint
31 December 2025
31 December 2026

Quick facts

Lead sponsorThe Catholic University of Korea
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2020
Primary completion31 December 2025
Estimated completion31 December 2026
Sites5 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

The Catholic University of Korea

Who can join

Adults 19 to 85, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, fractional flow reserve (FFR) is regarded as a gold-standard invasive method to define lesion-specific ischemia and FFR-guided PCI has been proven to reduce unnecessary revascularization and to enhance patient's clinical outcomes. Therefore, current guidelines recommend FFR measurement for intermediate coronary stenosis when there is no definite evidence of lesion-specific ischemia. However, previous evidences which well demonstrated the benefit of FFR-guided strategy were mostly generated from patients with stable coronary artery disease.4 FFR may be overestimated and the hemodynamic relevance of a coronary stenosis underestimated in patients with acute coronary syndrome (ACS).Its role in ACS patients still needs to be defined although several studies have recently published addressing the value of FFR-guided PCI in ACS. In fact, recent evidence suggests that culprit lesions of patients presenting with a non-ST-segment elevation myocardial infarction that were deferred based on a "negative" FFR have a relatively high event rate, calling into question the use of FFR in that patient population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fractional Flow Reserve

Trials testing the same drug.

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

Other The Catholic University of Korea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05896501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing